Surveillance and Diagnosis of HCC in Asia: Poster Presentation at ILCA 2023

A group of international and multidisciplinary clinical experts and Patient Advocacy Group representatives conducted a survey to investigate screening, therapeutic strategies and patient journeys of hepatocellular cancer (HCC) across the Asia Pacific region. These findings were presented at the poster tour at the opening ceremony of ILCA.

As liver cancer is the leading cause of cancer deaths in several Asian countries, these data can provide insight into the national approach to HCC management for each country, potential areas for improvement, and what to prioritise to shape national policies to improve outcomes for patients.

Clinical Takeaways

• The awareness of risk factors related to HCC should be increased among both primary care providers and the general Asian population
• Healthcare practitioners should monitor and manage treatment side effects, maintain a strong communication with patients and deploy trained nurses or case managers in the healthcare team to enhance patient education and support throughout the HCC patient journey
• There is a need to improve patient access to HCC treatment options known to extend survival rates, such as atezolizumab + bevacizumab

Authors

Prof. Rosmawati Mohamed*¹, Wendy Wang*², Tawesak Tanwandee³, Irsan Hasan⁴, Phuong Pham Cam⁵, Young-Suk Lim⁶, Sheng-Nan Lu⁷, Munisamy Murallitharan⁸, Huong Tran Thi Thanh⁹, Evy Ratnawati¹⁰, Wattana Sukeepaisarnjaroen¹¹, Mahir Karababa¹², Prof. Chee-Kiat Tan¹³

¹University of Malaya, Kuala Lumpur, Malaysia; ²Liver Disease Prevention and Treatment Research Foundation, Taiwan; ³Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ⁴Faculty of Medicine, University Indonesia/Ciptomangunkusumo Hospital, Indonesia; ⁵Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, and Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam; ⁶Department of Internal Medicine and Department of Gastroenterology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea; ⁷Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁸National Cancer Society of Malaysia, Jalan Raja Muda Abdul Aziz, Wilayah Persekutuan Kuala Lumpur, Malaysia; ⁹National Cancer Institute, Hanoi, and Vietnam and Hanoi Medical University, Hanoi, Vietnam; ¹⁰Indonesian Cancer Information and Support Center (CISC), Indonesia; ¹¹Faculty of Medicine, Khon Kaen University, Khon Kaen, Changwat Khon Kaen, Thailand; ¹²COR2ED, Basel, Switzerland; ¹³Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore